LONDON, Aug 10 (Reuters) - A British court has ruled that the country’s drugs cost-effectiveness watchdog can restrict access to medicines for Alzheimer’s disease to only the neediest patients, rejecting an appeal by drugmakers and charities.
LONDON, Aug 10 (Reuters) - A British court has ruled that the country’s drugs cost-effectiveness watchdog can restrict access to medicines for Alzheimer’s disease to only the neediest patients, rejecting an appeal by drugmakers and charities.
